SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now

EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Clinical Study

Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

Abi-Jaoude E; Chen L; Cheung P; Bhikram T; Sandor P ·The Journal of neuropsychiatry and clinical neurosciences ·2017 ·DOI: 10.1176/appi.neuropsych.16110310

Abstract

The authors retrospectively evaluated effectiveness and tolerability of cannabis in 19 adults with Tourette syndrome. Tics scores decreased by 60%, and 18 of the 19 participants were at least "much improved." Cannabis was generally well tolerated, although most participants reported side effects.

Methodology

Sample sizen = 19

Citation

View on PubMed

Other studies in this cluster

Neurology

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2017

RCT n=30

Neurology

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015

Neurology

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

Pain medicine (Malden, Mass.) · 2016

RCT

Neurology

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Expert review of pharmacoeconomics & outcomes research · 2016

Neurology

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Journal of clinical pharmacology · 2015

Neurology

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

European neurology · 2016

Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

Abstract

Methodology

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Contact us

Categories

Editions

Business of cannabis

Popular

Time is running out to nominate

Recent Searches

Popular Searches

Recent Searches

Popular Searches

Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

Abstract

Methodology

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Cannabis news, every Monday morning.

Time is running out to nominate